Browse all our past news

Usage of the new oral anticoagulants (NOACs), dabigatran, rivaroxaban, and apixaban, may be associated with lower medical costs (excluding drug costs) relative to warfarin, according to results from the RE-LY, ROCKET-AF, and ARISTOTLE clinical trials. These were presented at the American College of Cardiology’s (ACC’s) 61st Annual Scientific Session, held recently in Chicago.

Recruitment continues for the HARMONY trial (A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation), a randomised, pacemaker-patient-based trial to examine the efficacy and safety of dronedarone (Multaq,® Sanofi) and ranolazine (Ranexa,® Gilead Sciences) on AF burden.

A new chemical compound for the possible treatment of brain damage caused by stroke has been designed, produced and patented by researchers at the University of Copenhagen. The results of biological tests have just been published in Proceedings of the National Academy of Sciences of the United States of America.¹

Death is being prematurely diagnosed after failure to respond to cardiopulmonary resuscitation (CPR), causing unnecessary distress to families, according to a signal statement released recently by the UK’s National Patient Safety Agency (NPSA).

A new type of stem cell-seeded patch promotes healing after myocardial infarction (MI), according to a study published recently in the journal Stem Cells Translational Medicine.¹

Inadequate training or supervision of clinical staff, and failure to follow clinical protocols, are more important than shortage of equipment or staff as causes of harm to hospitalised patients in the developing world, according to a study published recently on bmj.com.¹

Dissatisfaction with limited chronic heart failure (CHF) therapies, and the fast-expanding patient population, are encouraging the development of new drug options and superior treatments, according to a new report by GlobalData.¹

Depression increases the risk of death in patients who have a coronary stent implanted, according to research presented at the 12th Annual Spring Meeting on Cardiovascular Nursing, held recently in Copenhagen, Denmark.

Living kidney donors are at no greater risk of cardiovascular disease (CVD) than the healthy general population, according to a study published recently on bmj.com.¹

The real-world clinical use of a renal denervation system (Symplicity,™ Medtronic, Inc.), across multiple conditions, is to be evaluated by two clinical initiatives announced recently.